Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- (-) Evidence for Decision Making
- (-) Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- (-) Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Audience
Display Only
Showing 84 Results
Considering the Needs of Older Patients in Value Assessments
When we consider health care value, how can we assess the challenges faced by older patients with multiple diseases and their caregivers when making unique choices about their treatment options? It’s…
Six Ways ICER Changes Benefit the Payer, Not the Patient
NPC Executive Vice President and Chief Science Officer Robert W. Dubois, MD, PhD, examines what more is needed to balance stakeholder needs and ensure that patients are an integral part of the value…
Latest ICER Report Relies on Incomplete Evidence, Inadequate Analyses
It’s troubling to see a new report from the Institute for Clinical and Economic Review (ICER) that used incomplete evidence and inadequate analyses.
More Than Just One Number: Assessing The Value of Innovative Treatments
In a commentary for Specialty Pharmacy Times, National Pharmaceutical Council (NPC) President and CEO Dan Leonard takes a closer look at what changes are needed to ensure that value assessments can…
NPC Weighs in on ICER’s Approaches to Valuing Cures
Within the last few years, we’ve seen the development of treatments to cure specific types of blindness, cancers and hepatitis C. In coming years, we’re anticipating the Food and Drug Administration…
Value Assessments: Incorporating Patient Benefits and Perspectives in ICER Reviews of Allergy and Asthma Treatments
Tonya Winders, CEO and President, Allergy & Asthma Network (AAN), discusses her involvement in the peanut allergy value assessment process and shares her experiences in working with her members…
NPC in AJMC: Why We Need Multiple Measures of Cost-Effectiveness in the US
In an editorial for The American Journal of Managed Care, NPC Chief Science Officer and Executive Vice President Dr. Robert Dubois explores the pitfalls of assigning only one organization the…
NAMI Highlights Concerns With ICER's Review of TRD
Seven percent of adults in the U.S. — an estimated 16 million people — experienced at least one major depressive episode in 2016 alone. Depression can be difficult to treat effectively because of…
Public Input Is a Key Way to Improve Value Assessment Process
This week, the Institute for Clinical and Economic Review (ICER) has announced that it is planning to revise its value assessment framework process. In a perfect world, every framework developer…
How Can We Elevate the Patient Voice in Value-Based Payment for Oncology?
A new study from the National Pharmaceutical Council (NPC) and Discern Health sheds new light on progress in making value-based reimbursement mechanisms, like accountable care, patient-centered.
In Value Assessment, Additional Voices Bring Much-needed Alternative Perspectives
In an interview published in the Journal of Clinical Pathways, the Innovation and Value Initiative details why value assessment is a critical field in the future of health care, highlights patient…
Case Study Shows Benefits of Engaging Employees in Health Benefit Design
As open enrollment season for health insurance gets underway, a new case study shows that employees who are meaningfully engaged in deliberating and designing their health care benefits may have a…
NPC in Specialty Pharmacy Times: Inconsistent Specialty Pharmaceutical Coverage Threatens Care Coordination, Continuity
In his latest column for Specialty Pharmacy Times, NPC President and Chief Executive Officer Dan Leonard explores research published in Health Affairs that sheds light on when and how payers cover…
Restrictions, Variations in Specialty Drug Coverage May Affect Physician and Patient Choices
According to a study from the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center and NPC, coverage of specialty medicines by major U.S. commercial health plans varies…
NPC in in Specialty Pharmacy Times: Aiming for Value Over Volume in Cancer Drug Spending
In his latest column for Specialty Pharmacy Times, NPC President Dan Leonard takes a closer look at a presidential panel's report on "Promoting Value, Affordability, and Innovation in Cancer Drug…
Managing PBMs: An Employer’s Perspective
During a webinar hosted by the Integrated Benefits Institute on March 5, Chuck Reynolds, consultant for Benfield, a Division of Gallagher Benefit Services, and Kristen Putnam, Director, Global…
Coverage Decisions May Drive Potential Health Care System Inefficiency
New research from Tufts Medical Center and the National Pharmaceutical Council indicates that patient access to therapies depends on factors other than cost and clinical benefit.
Where Are They Now: Checking In With Former NPC Intern Jan Hansen
Jan Hansen, PhD, currently Vice President, Evidence for Access Medical Unit, US Medical Affairs at Genentech, participated in NPC’s pharmaceutical internship program in 1982. Dr. Hansen chatted with…
NAMI Weighs in on Value Assessment and ICER Engagement
Andrew Sperling, Director of Legislative Advocacy for the National Alliance on Mental Illness (NAMI), caught up with NPC President Dan Leonard to chat about concerns raised by mental health advocates…
Where Are They Now: Checking In With Former NPC Intern Dan Danielson
Dan Danielson, MS, currently a senior clinical manager at Premera Blue Cross, participated in NPC’s pharmaceutical internship program in 1993. Mr. Danielson chatted with us to answer a few questions…